title: Urinary excretion of adenosine deaminase binding protein in neonates treated with tobramycin.
abstract: The potential tubulotoxicity of tobramycin and cefotaxim were assessed in neonates by measuring the urinary level of adenosine deaminase binding protein (ABP) and urinary alpha 1-microglobulin and beta 2-microglobulin. In a prospective study, 33 neonates who received tobramycin and cefotaxim for suspected neonatal sepsis were compared with 48 untreated newborns during the first 10 days of life. The urinary concentrations of ABP and its excretion rates, corrected for body weight and body surface area, were significantly increased from the 1st day of treatment. Urinary alpha 1-microglobulin and beta 2-microglobulin were not elevated under tobramycin and cefotaxim during the first 2 days of treatment. We conclude that ABP may be a sensitive marker for the detection of proximal renal tubular injury during tobramycin and cefotaxim treatments of neonates. The increase in urinary ABP which occurs before an elevation of urinary alpha 1-microglobulin and beta 2-microglobulin may reflect earlier structural than functional alterations. However, since none of the treated infants had signs of electrolyte disorders or glomerular dysfunction, the clinical relevance of ABP measurement should be reevaluated.
authors.affiliation: University of Freiburg, Children's Hospital, Germany.
authors.forename: N
authors.initials: N
authors.lastname: Gordjani
authors.forename: R
authors.initials: R
authors.lastname: Burghard
authors.forename: D
authors.initials: D
authors.lastname: Müller
authors.forename: H
authors.initials: H
authors.lastname: Mathäi
authors.forename: G
authors.initials: G
authors.lastname: Mergehenn
authors.forename: J U
authors.initials: JU
authors.lastname: Leititis
authors.forename: M
authors.initials: M
authors.lastname: Brandis
mesh_terms: D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy; D015415:Biomarkers / Q000652:urine; D002439:Cefotaxime / Q000009:adverse effects / Q000652:urine; D002511:Cephalosporins / Q000652:urine; D003404:Creatinine / Q000652:urine; D018819:Dipeptidyl Peptidase 4 / Q000652:urine*; D006801:Humans; D007231:Infant, Newborn; D011446:Prospective Studies; D014031:Tobramycin / Q000009:adverse effects* / Q000627:therapeutic use; D001613:beta 2-Microglobulin / Q000652:urine
chemical_list: D000900:Anti-Bacterial Agents; D015415:Biomarkers; D002511:Cephalosporins; D001613:beta 2-Microglobulin; D003404:Creatinine; D018819:Dipeptidyl Peptidase 4; D002439:Cefotaxime; D014031:Tobramycin